DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

Fisher Clinical Services UK Limited

Annual report and financial statements for the year ended 31 December 2021

Company registration number: 05281630

WEDNESDAY
ABB3UGLT
A17 24/08/2022 #227
COMPANIES HOUSE

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

FISHER CLINICAL SERVICES UK LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

Contents

	Page
Officers and Professional Advisers	3
Strategic Report for the Year Ended 31 December 2021	4
Directors' Report for the Year Ended 31 December 2021	8
Independent Auditors' report to the members of Fisher Clinical Services UK Limited	12
Financial Statements for the Year Ended 31 December 2021:	
• Profit and Loss Account	15
• Statement of Comprehensive Income	16
• Balance Sheet	17
• Statement of Changes in Equity	18
Notes to the Financial Statements for the Year Ended 31 December 2021	19

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

FISHER CLINICAL SERVICES UK LIMITED

OFFICERS AND PROFESSIONAL ADVISERS

Directors

A Smith
D Norman
E Cameron
W Syed

Company Secretary

Oakwood Company Secretary Limited
R Gregg

Registered office

3rd Floor
1 Ashley Road
Altrincham
Cheshire
WA14 2DT

Bankers

Barclays Bank
1 Churchill Place
London
E14 5HP

Solicitors

Addleshaw Goddard
100 Barbirolli Square
Manchester
M2 3AB

Independent auditors

PricewaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors
40 Clarendon Road
Watford
Hertfordshire
WD17 1JJ

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

FISHER CLINICAL SERVICES UK LIMITED

STRATEGIC REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

The directors present their strategic report on the company for the year ended 31 December 2021.

Review of the business and future developments

The Company is part of a global network and its principal activity is to support Pharma and Biotech companies with packaging and distribution services for clinical trial materials. This network includes sites in India, Switzerland, USA, Singapore, China, Japan and Latin America. The network is ultimately owned by Thermo Fisher Scientific Inc. though trades under the name of Fisher Clinical Services.

The directors are satisfied with the performance in the year following continuing uncertainty around the impact of COVID-19. Turnover has remained stable and in turn the margins have increased from 32% in 2020 to 36% in the current year. The margin improvement is a result of a change in product mix in the year with the company experiencing a decrease in turnover associated with a low margin service line and increased turnover with service lines attracting a higher margin. The underlying business remains strong with all areas ready to support future business growth.

The company has continued to develop a global distribution offering to support the movement of clinical trial materials and will continue to operate within its existing markets.

While the global novel strain of coronavirus (COVID-19) has had a significant impact on the economic activity around the world the company has not seen a material impact on its business results. The company had proactively assessed COVID-19's impact on its operations and took preventative measures to ensure the company could continue to service its clients' needs within the government guidelines. To support the response to COVID-19 the company has provided services to our Pharma and Biotech clients on several COVID-19 clinical trials. The situation will be continuously monitored going-forward, working with our clients and suppliers to ensure that the underlying business will remain strong for the foreseeable future.

Key performance indicators (KPI's)

The directors believe that the key performance indicators ('KPIs') are revenue, profitability, cash flow, On-Time and In Full for packaging services and On-Time Delivery for distribution services.

Revenue for the financial year was £135,769,000 (2020: £135,690,000) with the company continuing to retain and serve the strong base of strategic key customers (large pharma companies) and add new high potential as well as small and emerging customers.

Changes in product mix during 2021 has impacted gross profit margins, increasing it to 36% (2020: 32%) and operating margins which decreased to 17% (2020: 19%) for the year. While revenue and the margins have remained strong the impact of Covid-19 on resources led to a slight downturn in the company's operational indicators, with the impact being seen in the final quarter of 2020 and into the first quarter of 2021. Recovery plans were put in place during 2021 to help reach its target for On-Time and In-Full - packaging services of 90% and On-Time Delivery - distribution services of 99% for the year. On-Time Delivery - distribution services improved to a yearly average of 95% with 99% being achieved for the final four months of the year, however the company only achieved a yearly average for On-Time and In-Full - packaging services of 78% which is a decrease on the prior year's average of 84.3%. The company continues to work with the internal and external stakeholders to overcome the issues encountered during 2021 with the hope of reaching the 90% target during 2022.

The profit for the financial year was £47,641,000 (2020: £43,975,000) which will be transferred to reserves.

The net assets for the financial year were £95,062,000 (2020: £97,421,000).

The monthly average number of employees during the year was 626 and there were 658 employees at the end of the year.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

FISHER CLINICAL SERVICES UK LIMITED

STRATEGIC REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

Statement by the directors of their statutory duties in accordance with Section 172(1) of the Companies Act 2006

The directors of the company have acted in accordance with a set of general duties. These duties are detailed in section 172 of the Companies Act 2006 which is summarised as follows:

'Each director of the company has acted in the way they consider, in good faith, would be most likely to promote the success of the company for the benefit of its members as a whole, and in doing so have regard (amongst other matters) to:

- the likely consequences of any decision in the long term,
- the interests of the company's employees,
- the need to foster the company's business relationships with suppliers, customers and others,
- the impact of the company's operations on the community and the environment,
- the desirability of the company maintaining a reputation for high standards of business conduct,
- the need to act fairly as between members of the company.'

As part of the director induction process, a director is briefed on their duties and they can access professional advice on these from the company secretary. The following paragraphs summarise how the directors' fulfil their duties.

Risk management

As we continue to grow our business our risk environment also becomes more complex. It is therefore vital that we effectively identify, evaluate, manage and mitigate the risks we face and that we continue to evolve our approach to risk management.

For details of our principal risks and uncertainties and how we manage those risks, please refer to the principal risks section within the Strategic Report.

Business relationships

Our mission is to enable our customers to make the world healthier, cleaner and safer and as a result of this mission we have created a culture where our customers come first. Part of our business strategy is to continue to strengthen our company to be the partner customers rely on to help them achieve their goals. This is achieved through delivering a unique value proposition to our customers.

As a company we place great importance on building and maintaining strong relationships with our suppliers. The company is committed to meeting payment terms agreed with suppliers and we seek to resolve queries in an efficient and professional manner.

Our colleagues

None of our accomplishments would be possible without our team. Inspired by our mission, and grounded by our 4i values (integrity, intensity, innovation and involvement) this motivates our team to bring their best every day. It also helps us to attract and retain talent which is critical to our future.

We invest in our colleagues through numerous development programs that enrich their individual experiences, stress the importance of teams and build skills that set them up for success.

Further information can be found in the Directors' Report.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

Statement by the directors of their statutory duties in accordance with Section 172(1) of the Companies Act 2006 (continued)

Community and environment

Our mission is to enable our customers to make the world healthier, cleaner and safer. One way that we fulfil our Mission is by being a socially responsible community partner. Our giving strategy includes educational programs, colleague donations and volunteering.

Our signature STEM education programs connect students and colleagues through hands on and team based activities that highlight our technologies, make connections to careers in STEM and demonstrate how our company impacts the world.

To promote the generous spirit of our colleagues, our Charitable Giving Program provides a platform that allows them to contribute to causes that they feel passionately about. Through the program, employees can make direct donations to a charity of their choice, create a fundraiser - gathering greater support for a cause, or contribute to support a disaster relief campaign. Through our Employee Matching Gift program, we help employees make an even bigger impact by matching their contribution to eligible charities by 50%.

We feel it is important to support our community, throughout the year we encourage employees to take part in volunteering and charity events where our employees, together with our charity partners, take part in hands on volunteering.

The company is a part of Thermo Fisher Scientific Inc.'s global strategy to reduce our carbon footprint by 30% by 2030. As part of this global initiative we are committed to reviewing and reducing greenhouse gas emissions.

Principal risks and uncertainties

The management of the business is subject to a number of risks including commercial risk, price risk, credit risk, currency risk and interest rate cash flow risk. The mitigation of these risks has been outlined below.

Commercial risk

The company continues to improve its services and enhance its central quality systems in order to maintain and develop its market place penetration.

Financial risk management

The company's operations expose it to a variety of financial risks that include the effects of changes in credit risk, currency risk and interest rate cash flow risk and liquidity risk.

In order to ensure stability of cash out flows and hence manage interest rate risk, the company is supported by fellow group operations. The company does not use derivative financial instruments to manage interest rate costs and as such, no hedge accounting is applied.

Given the size of the company, the directors have not delegated the responsibility of monitoring financial risk management to a sub-committee of the board. The policies set by the board of directors are implemented by the company's finance department. The department has a policy and procedures manual that sets out specific guidelines to manage interest rate risk, credit risk and circumstances where it would be appropriate to use financial instruments to manage these.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

Principal risks and uncertainties (continued)

Credit risk

The company has implemented policies that require appropriate credit checks on potential customers before sales are made. The amount of exposure to any individual counterparty is subject to a limit, which is continually reviewed by the senior management team.

Currency risk

The company is exposed to currency risk as a result of its operations. However, given the size of the company's operations, the cost of managing the exposure to currency risk through the use of derivative financial instruments exceeds any potential benefits, and as such no hedge accounting is applied. The company operates foreign currency bank accounts in order to offset foreign currency receipts and payments.

Interest rate cash flow risk

The company has both interest bearing assets and interest bearing liabilities. Interest bearing assets include cash balances, all of which earn interest at fixed rate. Interest bearing liabilities include only loan notes and intercompany loans, which bear interest at variable rates.

Liquidity risk

The company monitors its net current asset position to ensure it is able to meet its liabilities as they fall due.

COVID-19

Risks and uncertainties associated with the ongoing COVID-19 global pandemic will continue to affect the company's operations through 2022. The extent and duration of such impacts are uncertain and may require changes to estimates.

Russia and Ukraine conflict

The company has assessed the risks and uncertainties associated with the current conflict between Russia and Ukraine and they do not believe that they will materially affect the company's operation. Management will continue to work closely with the internal Global Trade Compliance team and follow their guidance in regards to on-going relationships with our networked site in Russia and third-party depot sites in Ukraine.

On behalf of the board

DocuSigned by:
Euan Cameron
231F19E0E41648D...

E Cameron

Director

14 July 2022

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

FISHER CLINICAL SERVICES UK LIMITED

DIRECTORS' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

The directors present their report and the audited financial statements of the company for the year ended 31 December 2021.

Future developments

Future developments are deemed to be of strategic importance to the company and as such have been outlined within the strategic report.

Dividends

The directors approved and paid an interim dividend of £0.71 (2020: £0.67) per ordinary share, amounting to £50,000,000 in 2021 (2020: £46,700,000) and do not recommend the payment of a final dividend.

Financial risk management and research and development

Disclosures relating to these areas are included in the strategic report.

Directors

The directors who held office during the year and up to the date of signing the financial statements are given below:

A Smith
D Norman
E Cameron
W Syed

Third party indemnity provision

The company has made qualifying third party indemnity provisions for the benefit of its directors (which extend to the performance of any duties as a director of any associated company) and these were in force during the year and they remain in force at the date of this report.

Employees

The company recognises the benefit of keeping employees informed of the progress of the business and of involving them in the company's performance and, accordingly, maintains regular communications with employees and has well established consultation arrangements that include the following:

- systematic provision of relevant information to employees;
- regular consultation with employees or their representatives so that the employees' views may be taken into account in making decisions that are likely to affect their interests;
- encouragement of employees' participation in the group's performance by employee share schemes; and
- achieving awareness on the part of all employees of the financial and economic factors affecting the group's performance.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

Disabled employees

The company gives full consideration to applications for employment from disabled persons where the requirements of the job can be adequately fulfilled by a disabled person.

Where existing employees become disabled, it is the company's policy wherever practicable to provide continuing employment under normal terms and conditions and to provide training and career development and promotion wherever appropriate.

Statement of directors' responsibilities in respect of the financial statements

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulation.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have prepared the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law).

Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing the financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- state whether applicable United Kingdom Accounting Standards, comprising FRS 102, have been followed, subject to any material departures disclosed and explained in the financial statements;
- make judgements and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006.

The directors are responsible for the maintenance and integrity of the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Stakeholder engagement statement

For details on stakeholder engagements, please see the 'Business Relationships' section of the Strategic Report.

Employee engagement statement

For details on employee engagements, please see the 'Our Colleagues' section of the Strategic Report.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

Streamlined Energy and Carbon Reporting (SECR)

The company fulfils the statutory requirements for Streamlined Energy and Carbon Reporting which includes disclosure of the Company's carbon emissions. Under the Companies Act 2006 / SECR Regulations, 'Large' companies' are required to report their annual emissions in their Directors' report.

Fisher Clinical Services UK Limited's Streamlined Energy and Carbon Reporting statement covers the reporting period 31 January 2021 to 31 December 2021 and has been prepared in line with the requirements of the Streamlined Energy and Carbon Reporting regulations and the relevant areas of the Greenhouse Gas ('GHG') Protocol Corporate Accounting and Reporting Standard.

A 'Dual Reporting' methodology has been used to indicate emissions using UK electricity grid average emission factors (known as the 'Location based' method), and also emissions using supplier specific generation emission factors (the 'Market Based' method).

'Location based' Method

The total energy consumption for 2021 was 6,151,368 kWh equating to 1,381 tCO_2 e

Emissions from combustion of gas (Scope 1)	**155 tCO_2 e**
Emissions from combustion of fuel for transport purposes (Scope 1)	**1 tCO_2 e**
Emissions from purchased electricity (Scope 2)	**1,114 tCO_2 e**
Emissions from Transmission and Distribution (Scope 3)	**99 tCO_2 e**
Emissions from business travel in rental cars or employee-owned vehicles where company is responsible for purchasing the fuel (Scope 3)	**14 tCO_2 e**

Carbon intensity: Emissions of tCO2e/£m sales revenue during 2021 was 10 tCO_2 e

'Market Based' Method

The total energy consumption for 2021 was 6,151,368 kWh equating to 169 tCO_2 e

Emissions from combustion of gas (Scope 1)	**155 tCO_2 e**
Emissions from combustion of fuel for transport purposes (Scope 1)	**1 tCO_2 e**
Emissions from purchased electricity (Scope 2)	**0.000 tCO_2 e**
Emissions from Transmission and Distribution (Scope 3)	**0.000 tCO_2 e**
Emissions from business travel in rental cars or employee-owned vehicles where company is responsible for purchasing the fuel (Scope 3)	**14 tCO_2 e**

Carbon intensity: Emissions of tCO2e/£m sales revenue during 2021 was 1 tCO_2 e

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

Energy efficiency action taken:

- An enterprise-wide review of the company global carbon reduction goal took place in May & June 2021. This used 6 sites as representative of the organisation's varied operations.
- This review informed the corporate strategic planning group and resulted in a change to 30% reduction in GHG emissions by 2030 and net zero carbon emissions by 2050.
- A global steering and project management office have been set up to drive to achieve the targets.
- In Q4, net zero carbon assessments were initiated in 15 global sites, which represents 50% of the organisation's carbon emissions.
- Further investments in electric vehicles have been made to aid in the movement of goods and equipment around the three sites, rather than using diesel vans that were previously leased.
- The two electronic points installed for the above vehicles have also been made available to all employees.
- The Air Handling Units and Chiller Units are being replaced, making these more energy-efficient. These also utilise new f-gas which is less damaging to the ozone. The plan to replace these Units continues into 2022.

Type	Comparison reporting year 2020	Current reporting year 2021
Total energy consumption (kWh)	5,811,162 kWh	6,151,368 kWh
Associated Carbon Emissions (tCO2e)	1,423 tCO2e	1,381 tCO2e
Metric - Emissions of tCO2e per £m turnover	10 tCO2e	10 tCO2e

Directors' confirmations

In the case of each director in office at the date the Directors' Report is approved:

- so far as the director is aware, there is no relevant audit information of which the company's auditors are unaware; and
- they have taken all the steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

Independent Auditors

The auditors, PricewaterhouseCoopers LLP, have indicated their willingness to continue in office and a resolution concerning their reappointment will be proposed at the annual general meeting.

On behalf of the board

DocuSigned by:
Euan Cameron
231F19E0E4164BD...

E Cameron
Director

14 July 2022

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF FISHER CLINICAL SERVICES UK LIMITED

Report on the audit of the financial statements

Opinion

In our opinion, Fisher Clinical Services UK Limited's financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2021 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law); and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements, included within the Annual report and financial statements (the "Annual Report"), which comprise: the Balance Sheet as at 31 December 2021; the Profit and Loss Account, the Statement of Comprehensive Income and the Statement of Changes in Equity for the year then ended; and the notes to the financial statements, which include a description of the significant accounting policies.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remained independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Conclusions relating to going concern

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the company's ability to continue as a going concern.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Reporting on other information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF FISHER CLINICAL SERVICES UK LIMITED

performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Strategic report and Directors' report, we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on our work undertaken in the course of the audit, the Companies Act 2006 requires us also to report certain opinions and matters as described below.

Strategic report and Directors' report

In our opinion, based on the work undertaken in the course of the audit, the information given in the Strategic report and Directors' report for the year ended 31 December 2021 is consistent with the financial statements and has been prepared in accordance with applicable legal requirements.

In light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we did not identify any material misstatements in the Strategic report and Directors' report.

Responsibilities for the financial statements and the audit

Responsibilities of the directors for the financial statements

As explained more fully in the Statement of directors' responsibilities in respect of the financial statements, the directors are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The directors are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Based on our understanding of the company and industry, we identified that the principal risks of non-compliance with laws and regulations related to compliance with the Companies Act 2006, and we considered the extent to which non-compliance might have a material effect on the financial statements. We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to posting unusual journal entries to increase revenue or profit and management bias in respect of accounting estimates. Audit procedures performed by the engagement team included:

- Discussions with management including consideration of any known or suspected incidents of non-compliance with laws and regulations and fraud.
- Using Computer Assisted Audit Techniques to analyse all journals to identify any unexpected account combination and test those which met our risk criteria.
- Testing accounting estimates for possible management bias.
- Incorporating an element of unpredictability into our audit testing, as required by ISA 240.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF FISHER CLINICAL SERVICES UK LIMITED

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

Use of this report

This report, including the opinions, has been prepared for and only for the company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

Other required reporting

Companies Act 2006 exception reporting

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- we have not obtained all the information and explanations we require for our audit; or
- adequate accounting records have not been kept by the company, or returns adequate for our audit have not been received from branches not visited by us; or
- certain disclosures of directors' remuneration specified by law are not made; or
- the financial statements are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.

Alex Crompton (Senior Statutory Auditor)
for and on behalf of PricewaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors
Watford
14 July 2022

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

PROFIT AND LOSS ACCOUNT

	Note	Year ended 31 December 2021 £'000	2020 £'000
Turnover	3	**135,769**	135,690
Cost of sales		**(87,365)**	(92,444)
Gross profit		**48,404**	43,246
Distribution costs		**(8,047)**	(6,293)
Administrative expenses		**(16,679)**	(11,017)
Operating profit	4	**23,678**	25,936
Income from shares in group undertakings	11	**20,897**	21,186
Profit before interest and taxation		**44,575**	47,122
Interest receivable and similar income	6	**—**	—
Interest payable and similar expenses	6	**(300)**	(380)
Net interest expense	6	**(300)**	(380)
Profit before taxation		**44,275**	46,742
Tax on profit	7	**3,366**	(2,767)
Profit for the financial year		**47,641**	43,975

Results in the current and previous financial year are from continuing operations only.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

FISHER CLINICAL SERVICES UK LIMITED

STATEMENT OF COMPREHENSIVE INCOME

	Year ended 31 December	
	2021	2020
	£'000	£'000
Profit for the financial year	**47,641**	43,975
Other comprehensive income:		
Total tax on components of other comprehensive income	—	—
Other comprehensive income for the year, net of tax	—	—
Total comprehensive income for the year	**47,641**	43,975

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

FISHER CLINICAL SERVICES UK LIMITED

BALANCE SHEET

	Note	As at 31 December 2021 £'000	2020 £'000
Fixed assets			
Intangible assets	9	**32,342**	38,411
Tangible assets	10	**25,414**	25,691
Investments	11	**725**	725
		58,481	64,827
Current assets			
Inventories	12	**1,292**	5,874
Debtors	13	**72,225**	70,729
Cash at bank and in hand		**364**	65
		73,881	76,668
Creditors: amounts falling due within one year	14	**(24,767)**	(31,531)
Net current assets		**49,114**	45,137
Total assets less current liabilities		**107,595**	109,964
Creditors – amounts falling due after more than one year	15	**(12,533)**	(12,543)
Net assets		**95,062**	97,421
Capital and reserves			
Called up share capital	20	**70,000**	70,000
Share premium account		**—**	—
Retained earnings		**25,062**	27,421
Total equity		**95,062**	97,421

The notes on pages 19 to 40 are an integral part of these financial statements.

The financial statements on pages 15 to 40 were authorised for issue by the board of directors on 14 July 2022 and were signed on its behalf

DocuSigned by:
Euan Cameron
231F19E0E41648D...

E Cameron

Director

Fisher Clinical Services UK Limited

Company registration number: 05281630

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

FISHER CLINICAL SERVICES UK LIMITED

STATEMENT OF CHANGES IN EQUITY

	Note	Called-up share capital	Retained earnings [1]	Total equity
		£'000	£'000	£'000
Balance as at 1 January 2020		70,000	30,146	100,146
Profit for the financial year		—	43,975	43,975
Other comprehensive income for the year		—	—	—
Total comprehensive income for the year		—	43,975	43,975
Dividends	20	—	(46,700)	(46,700)
Total transactions with owners, recognised directly in equity		—	(46,700)	(46,700)
Balance as at 31 December 2020		70,000	27,421	97,421
Balance as at 1 January 2021		70,000	27,421	97,421
Profit for the financial year		—	47,641	47,641
Other comprehensive income for the year		—	—	—
Total comprehensive income for the year		—	47,641	47,641
Dividends	20	—	(50,000)	(50,000)
Total transactions with owners, recognised directly in equity		—	(50,000)	(50,000)
Balance as at 31 December 2021		**70,000**	**25,062**	**95,062**

[1] Retained earnings represents accumulated comprehensive income for the current financial year and prior financial year plus share-based payments adjustments and related tax credits, charges from the parent company for share-based payments less dividends paid.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

FISHER CLINICAL SERVICES UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

1. General Information

Fisher Clinical Services UK Limited ('the company') is registered in England and supports Pharma and Biotech companies with packaging and distribution of clinical trial materials. The company is incorporated in the United Kingdom as a private company, limited by shares, and is part of a global network with sites in the UK, India, Switzerland, USA, Singapore, China, Japan and Latin America and make sales worldwide.

Statement of compliance

The individual financial statements of Fisher Clinical Services UK Limited have been prepared in compliance with United Kingdom Accounting Standards, including Financial Reporting Standard 102, "The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland" ("FRS 102") and the Companies Act 2006.

Summary of significant accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Basis of preparation

These financial statements have been prepared on a going concern basis, under the historical cost convention in accordance with the Companies Act 2006 and applicable accounting standards in the United Kingdom.

The preparation of financial statements in conformity with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 2.

Going Concern

The company meets its day-to-day working capital requirements through its bank facilities. The current economic conditions continue to create uncertainty over (a) the level of demand for the company's products; and (b) the availability of bank finance for the foreseeable future. The company's forecasts and projections, taking account of reasonably possible changes in trading performance, show that the company should be able to operate within the level of its current facilities.

Risks and uncertainties associated with the ongoing COVID-19 global pandemic will continue to affect the company's operations through 2022. The extent and duration of such impacts are uncertain and may require changes to estimates.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

1. General Information (continued)

Exemptions for qualifying entities under FRS 102

FRS 102 allows a qualifying entity certain disclosure exemptions.

Cash flow statement and related party disclosures
The company is included in the consolidated financial statements of Thermo Fisher Scientific Inc. which are publicly available. Consequently, as the company is a 100% owned subsidiary, the company has taken advantage of the exemption, under FRS 102 paragraph 1.12(b), from preparing a statement of cash flows, on the basis that it is a qualifying entity and its ultimate parent company, Thermo Fisher Scientific Inc., includes the company's cash flows in its own consolidated financial statements. The company is also exempt under the terms of FRS 102 paragraph 33.1 from disclosing related party transactions with entities that are part of the Thermo Fisher Scientific Inc. group (see note 23).

Share-based payments

The company has taken advantage of the exemption under FRS 102 para 26.16 where the company is a member of a group share-based payment arrangement and where the company's expense is based on a reasonable allocation and disclosed in full in the consolidated group financial statements.

Consolidated financial statements

The financial statements contain information about Fisher Clinical Services UK Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under section 401 of the Companies Act 2006 from the requirement to prepare consolidated financial statements as it and its subsidiary undertakings are included by full consolidation in the consolidated financial statements of its ultimate parent company, Thermo Fisher Scientific Inc., a company incorporated in the United States of America (see note 24).

Foreign currency

(i) Functional and presentation currency

The company's functional and presentation currency is the pound sterling.

(ii) Transactions and balances

Transactions in foreign currencies are translated into sterling at the exchange rate ruling at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Any gain or loss arising from a change in exchange rates subsequent to the date of the transactions is included as an exchange gain or loss in the Profit and Loss account except when deferred in other comprehensive income as qualifying cash flow hedges.

Non-monetary items measured at historical costs are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses are presented in the profit and loss account within 'Cost of sales'.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

1. General Information (continued)

Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable and represents the amount received for services rendered net of discounts and rebates allowed by the company and value added taxes.

Duty revenue is measured as described above but net of directly attributable costs to more accurately reflect the underlying nature of the transaction as an agent.

The company bases its estimate of returns on historical results, taking into consideration the type of customer, the type of transaction and the specifics of each arrangement.

Where the consideration receivable in cash or cash equivalents is deferred, and the arrangement constitutes a financing transaction, the fair value of the consideration is measured as the present value of all future receipts using the imputed rate of interest.

Revenue from services rendered is recognised when the service is delivered apart from freight revenue which is recognised over time rather than upon delivery.

Interest income

Interest income is recognised using the effective interest rate method.

Dividend income

Dividend income is recognised when the right to receive payment is established.

Employee benefits

The company provides a range of benefits to employees, including annual bonus arrangements, paid holiday arrangements and defined contribution pension plans.

(i) Short term benefits

Short term benefits, including holiday pay and other similar non-monetary benefits, are recognised as an expense in the year in which the service is received.

(ii) Defined contribution pension plans

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.

For defined contribution schemes the amount charged to the profit and loss account in respect of pension costs is the contribution payable in the year. Differences between contributions payable and actually paid are shown as either accruals or prepayments in the balance sheet.

Annual bonus plan

The company operates an annual bonus plan for employees. An expense is recognised in the profit and loss account when the company has a legal or constructive obligation to make payments under the plan as a result of past events and a reliable estimate of the obligation can be made.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

1. General Information (continued)

Share-based payments

The company's employees have been granted share options by the ultimate parent company, Thermo Fisher Scientific Inc. The company makes use of the exemption in Section 26 of FRS 102 to account for the expense based on a reasonable allocation of the parent company's total expense. The company has calculated its allocation of the parent company's total expense based on the number of participating employees in the company compared to the number of participating employees in the group. The company also consider an allocation based on the relative remuneration cost of the relevant employees and considered that this gave rise to no significant difference in the allocated costs.

Taxation

Taxation expense for the period comprises current and deferred tax recognised in the reporting period. Tax is recognised in the profit and loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case tax is also recognised in other comprehensive income or directly in equity respectively.

Current or deferred taxation assets and liabilities are not discounted.

(i) Current tax

Current tax is the amount of income tax payable in respect of the taxable profit for the year or prior years. Tax is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the period end. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

(ii) Deferred tax

Deferred tax arises from timing differences that are differences between taxable profits and total comprehensive income as stated in the financial statements. These timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements.

Deferred tax is recognised on all timing differences at the reporting date except for certain exceptions. Unrelieved tax losses and other deferred tax assets are only recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Intangible assets

Goodwill

Goodwill represents the excess of the fair value of the consideration given over the fair value of the identifiable net assets acquired. Under the FRS102 section 18 and 19, goodwill arising on acquisitions has been capitalised and is being amortised over 20 years, being the period expected to benefit. The company evaluates the carrying value of goodwill in each financial year to determine if there has been an impairment in value, which would result in the inability to recover the carrying amount. When it is determined that the carrying value exceeds the recoverable amount, the excess is written off to the profit and loss account.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

1. General Information (continued)

Tangible assets

Tangible fixed assets are stated at historic purchase cost, net of accumulated depreciation and any provision for impairment. Cost includes the original purchase price of the asset and costs attributable to bringing the asset into its working condition for its intended use.

Land and buildings

Land and buildings include freehold and leasehold factories and offices. Land and buildings are stated at cost (or deemed cost for land and buildings held at valuation at the date of transition to FRS 102) less accumulated depreciation and accumulated impairment losses.

The difference between depreciation based on the deemed cost charged in the profit and loss account and the asset's original cost is transferred from revaluation reserve to retained earnings.

Plant, machinery and equipment

Plant, machinery and equipment are stated at cost less accumulated depreciation and accumulated impairment losses.

Depreciation and residual values

Freehold land is not depreciated. The fixed assets have been depreciated on a straight line basis at rates calculated to reduce the net book value of each asset to its estimated residual value by the end of its expected useful economic life in the company's business, and the rates are as follows:

Freehold land and buildings	– 10 to 30 years
Plant, machinery and equipment	– 3 to 10 years

Freehold land and assets under the course of construction are not depreciated.

The assets' residual values and useful lives are reviewed, and adjusted, if appropriate, at the end of each reporting period. The effect of any change is accounted for prospectively.

Repairs, maintenance and minor inspection costs are expensed as incurred.

Assets in the course of construction

Assets under the course of construction are depreciated when they first come into use.

Derecognition

Tangible assets are derecognised on disposal or when no future economic benefits are expected. On disposal, the difference between the net disposal proceeds and the carrying amount is recognised in profit or loss and included in 'Cost of sales'.

Leased assets

At inception the company assesses agreements that transfer the right to use assets. The assessment considers whether the arrangement is, or contains, a leased based on the substance of the arrangement.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

1. General Information (continued)

Leased Assets (continued)

Finance leased assets

Finance leases are capitalised at commencement of the lease at the fair value of the asset or, if lower, the present value of the minimum lease payments calculated using the interest rate implicit in the lease. Where the implicit rate cannot be determined the company's incremental borrowing rate is used.

Incremental direct costs, incurred in negotiating and arranging the lease, are included in the cost of the asset.

Assets are depreciated over the shorter of the lease term and estimated useful life of the asset. Assets are assessed for impairment at each reporting date.

The capital element of lease obligations is recorded as a liability on inception of the arrangement. Lease payments are apportioned between capital repayment and finance charge, using the effective rate method, to produce a constant rate of charge on the balance of the capital repayments outstanding.

Operating leased assets

Leases that do not transfer all the risks and rewards of ownership are classified as operating leases. Payments under operating leases are charged to the profit and loss account on a straight-line basis over the period of the lease.

Investments

Investments held as fixed assets are stated at cost less any provision for impairment. Impairment reviews are performed by the directors when there has been an indication of potential impairment.

Inventories

Inventories are stated at the lower of cost and estimated selling price less costs to complete and sell. Inventories are recognised as an expense in the year in which the related revenue is recognised.

Raw materials and consumables are valued at purchase cost on a first in, first out basis.

At the end of each reporting year inventories are assessed for impairment. If an item of inventory is impaired, the identified inventory is reduced to its selling price less costs to complete and sell and an impairment charge is recognised in the profit and loss account. Where a reversal of the impairment is recognised the impairment charge is reversed, up to the original impairment loss, and is recognised as a credit in the profit and loss account.

Cash and cash equivalents

Cash and cash equivalents includes cash in hand and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Provisions and contingencies

Provisions

Provisions are recognised when the company has a present legal or constructive obligation as a result of past events; it is probable that an outflow of resources will be required to settle the obligation; and the amount of the obligation can be estimated reliably.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

1. General Information (continued)

Provisions and contingencies (continued)

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

Financial instruments

The company has chosen to adopt Sections 11 and 12 of FRS 102 in respect of financial instruments.

Financial assets

Basic financial assets, including trade and other debtors, cash and bank balances and investments in commercial paper, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities

Basic financial liabilities, including trade and other creditors, and loans from fellow group companies, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

The company does not currently apply hedge accounting for interest rate and foreign exchange derivatives.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Offsetting

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

1. General Information (continued)

Distributions to equity holders

Dividends and other distributions to company's shareholders are recognised as a liability in the financial statements in the year in which the dividends and other distributions are approved by the company's shareholders. These amounts are recognised in the statement of changes in equity.

Related party transactions

The company discloses transactions with related parties which are not wholly owned with the same group. It does not disclose transactions with members of the same group that are wholly owned.

2. Critical accounting judgements and estimation uncertainty

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. There are no estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities within the next financial year.

3. Turnover

Turnover by geography

	2021	2020
	£'000	£'000
United Kingdom	**45,756**	39,458
Rest of Europe	**33,660**	23,209
Rest of World	**56,353**	73,023
	135,769	135,690

Turnover by nature

	2021	2020
	£'000	£'000
Rendering of services	**135,769**	135,690
	135,769	135,690

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

4. Operating profit

The operating profit is stated after charging/(crediting):

	Note	2021 £'000	2020 £'000
Wages and salaries		**25,800**	21,611
Social security costs		**2,485**	2,422
Other pension costs	**17**	**1,241**	1,097
Share-based payments	**8**	**894**	811
Staff costs		**30,420**	25,941
Reorganisation expense		**—**	—
Loss on disposal of tangible assets		**20**	7
Impairment of trade receivables		**417**	164
Amortisation of intangible assets (included in 'administrative expenses')		**6,069**	6,069
Impairment of inventory (included in 'cost of sales')		**(12)**	22
Operating lease charges			
- Land and buildings		**113**	135
Depreciation of tangible fixed assets			
- Owned assets		**2,274**	2,062
Foreign exchange loss		**341**	324
Audit fees payable to the company's auditors for the audit of the company		**109**	105

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

FISHER CLINICAL SERVICES UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

5. Employees and directors

By activity	2021 Number	2020 Number
Average monthly numbers of persons employed (including directors) by the company during the year was:		
Sales and marketing	**127**	120
Manufacturing	**446**	373
Administration	**53**	48
	626	541

Directors

Directors' emoluments include an allocation of Directors' emoluments which were borne by another group company, Thermo Electron (Management Services) Limited for their service to the company.

	2021 £'000	2020 £'000
Aggregate emoluments	**16**	104
Aggregate amounts (including shares) receivable under long-term incentive schemes	**1**	32
Company contributions to defined contribution pension scheme	**1**	6
	18	142

Retirement benefits accrued to no directors (2020: no directors) under a defined benefit scheme. Retirement benefits accrued to 4 (2020: 4) directors under a money purchase pension scheme.

During the year 3 directors (2020: 3 directors) exercised options over shares of Thermo Fisher Scientific Inc.

In 2021 4 (2020: 4) directors were entitled to shares under a long-term incentive scheme. The cost of share-based payments is not material to these financial statements and therefore has not been accounted for.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

FISHER CLINICAL SERVICES UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

6. Net interest (expense) / income

Interest receivable and similar income	**2021**	2020
	£'000	£'000
Bank interest receivable	**—**	—
Interest receivable from group undertakings	**—**	—
Other interest receivable	**—**	—
Total interest income on financial assets not measured at fair value through profit or loss	**—**	—
Total interest receivable and similar income	**—**	—

Interest payable and similar expenses	**2021**	2020
	£'000	£'000
Finance lease interest	**(1)**	(1)
Interest payable to group undertakings	**(261)**	(379)
Other interest payable	**(38)**	—
Total interest expense on financial liabilities not measured at fair value through profit or loss	**(300)**	(380)
Total interest payable and similar expenses	**(300)**	(380)

Net interest (expense) / income	**2021**	2020
	£'000	£'000
Total interest receivable and similar income	**—**	—
Total interest payable and similar expenses	**(300)**	(380)
Net interest (expense) / income	**(300)**	(380)

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

7. Tax on profit

Tax charge / (credit) included in profit and loss

	Note	2021 £'000	2020 £'000
Current tax			
UK corporation tax on profits of the year		—	3,192
Foreign tax relief		—	(1)
Withholding tax paid		—	2
Adjustment in respect of prior years		**(3,191)**	—
Total current tax		**(3,191)**	3,193
Deferred tax			
Origination and reversal of timing differences		**447**	(206)
Impact of changes in tax rates		**(614)**	(229)
Adjustments in respect of prior periods		**(8)**	9
Total deferred tax	18	**(175)**	(426)
Tax on profit		**(3,366)**	2,767

Reconciliation of tax charge / (credit):

The tax assessed for the year is lower (2020: lower) than the standard rate of corporation tax in the UK 19.00% (2020: 19.00%). The differences are outlined below:

	2021 £'000	2020 £'000
Profit on ordinary activities before taxation	**44,275**	46,742
Profit before taxation multiplied by the standard rate of corporation tax in the UK 19% (2020: 19%)	**8,412**	8,881
Effects of:		
Expenses not deductible for tax purposes	**1,166**	1,156
Impact of deferred tax rate change	**(614)**	(229)
Employee share scheme	**38**	(54)
Group relief for nil consideration	**(5,424)**	(3,192)
Non taxable dividend income	**(3,970)**	(4,025)
Adjustment in respect of prior periods	**(3,199)**	9
Depreciation on ineligible assets	**225**	221
Total tax charge / (credit) for the year	**(3,366)**	2,767

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

7. Tax on profit (continued)

Factors that may affect future tax charges:

The UK headline corporation tax for the period was 19% (2020: 19%). In the Spring Budget on 3 March 2021 it was announced that the UK Corporation Tax rate would increase to 25% with effect from 1 April 2023 and was substantively enacted on 24 May 2021. Therefore at the balance sheet date deferred tax is measured at the rate that will be enacted or substantively enacted on the date when then underlying temporary differences are expected to unwind.

8. Share-based payments

Under the Employee Incentive Programme (EIP) options and Restricted Stock Units (RSUs) are granted to employees of this company in the shares of the ultimate parent company, Thermo Fisher Scientific Inc. Options are granted with a fixed exercise price equal to the market price of the shares under option at the date of the grant. Employees do not pay an exercise price for RSUs. The contractual life of an option is 7 years from the date of the grant. Historically, options are annually granted in February or March. Options and RSUs vest over three or four years from the grant date, with equal proportions being exercisable on each anniversary, subject to continued employment. New options and RSUs were granted in 2017 and 2018 under the ThermoFisher Scientific Inc. plan.

The company recognises an equity-settled share-based payment expense based on a reasonable allocation of the total charge for the group. This allocation is the total charge for the group prorated for the number of participating employees of the company.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

9. Intangible assets

	Goodwill £'000	Total £'000
Cost		
At 1 January 2021	121,376	**121,376**
Additions	—	—
Transfers	—	—
Disposals	—	—
At 31 December 2021	121,376	**121,376**
Accumulated amortisation and impairment of goodwill		
At 1 January 2021	82,965	**82,965**
Charge for the year	6,069	**6,069**
Disposals	—	—
At 31 December 2021	89,034	**89,034**
Net book value		
At 31 December 2021	**32,342**	**32,342**
At 31 December 2020	38,411	38,411

Goodwill arose on the acquisition by this company of the "Fisher Clinical Services" trade and assets from a fellow group company during 2007.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

FISHER CLINICAL SERVICES UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

10. Tangible assets

	Freehold land and buildings	Plant, machinery and equipment	Assets in course of construction	Total
	£'000	£'000	£'000	£'000
Cost				
At 1 January 2021	28,463	9,467	4,599	42,529
Additions	—		3,466	3,466
Transfers	805	1,615	(2,420)	—
Disposals	(353)	(903)	(1,432)	(2,688)
At 31 December 2021	28,915	10,179	4,213	43,307
Accumulated depreciation				
At 1 January 2021	10,996	5,842	—	16,838
Charge for the year	1,454	820	—	2,274
Disposals	(329)	(890)	—	(1,219)
At 31 December 2021	12,121	5,772	—	17,893
Net book value				
At 31 December 2021	16,794	4,407	4,213	25,414
At 31 December 2020	17,467	3,625	4,599	25,691

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

11. Investments

	Subsidiary undertakings £'000
As at 1 January 2021	725
Additions	—
Disposals	—
Provision for impairment	—
As at 31 December 2021	**725**

Analysed as:

	2021 £'000
Fisher Clinical Services PTE Limited	725
	725

Fixed asset investments comprise ordinary shares in Fisher Clinical Services PTE Limited, which is not publicly traded.

The directors believe that the carrying value of the investments is supported by their underlying net assets.

The company also owns 0.315% of the ordinary share capital of Fisher Biopharma Services (India) Private Limited. The carrying value of the investment is £nil.

The company's subsidiaries were as follows:

The company owns 100% of the ordinary share capital of its subsidiary, Fisher Clinical Services PTE Limited (2020: 100%). Fisher Clinical Services PTE Limited is incorporated in Singapore. During the year dividends of £20,897,000 (2020: £21,181,000) were received from Fisher Clinical Services PTE Limited. The address of the registered office is 38 Beach Road, 29-11 South Beach Tower, Singapore, 189767.

	Incorporated in	Share Class	Percentage held	Activity
Fisher Clinical Services PTE Limited	Singapore	Ordinary	100%	Trading

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

12. Inventories

	2021 £'000	2020 £'000
Raw materials and consumables	**1,292**	5,874
	1,292	5,874

There is no significant difference between the replacement cost of work in progress and finished goods and goods for resale and their carrying amounts.

Inventories are stated after provisions for impairment of £10,391 (2020: £22,029).

13. Debtors

	2021 £'000	2020 £'000
Trade debtors	**50,264**	44,931
Amounts owed by group undertakings	**7,057**	3,647
Other debtors	**1,160**	—
Deferred tax asset	**2,560**	2,385
Prepayments and accrued income	**11,184**	19,766
	72,225	70,729

Trade debtors includes £nil (2020: £nil) falling due after more than year.

Cash held by group entities under the cash sweep arrangement of £2,187,562 (2020: £782,251) is included under debtors as amounts owed by group undertakings. The management company, Life Technologies Finance Limited, shall effect quarterly the calculation for distributions of debit interest or credit interest at rate of SONIA + 0.5% among the parties and settle this accordingly on the in-house bank accounts of the participant with the management company. This is unsecured and repayable on demand.

The remaining amounts owed by group undertakings of £4,869,337 (2020: £2,864,303) are unsecured, interest free and repayable on demand.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

14. Creditors: amounts falling due within one year

	2021 £'000	2020 £'000
Trade creditors	**3,399**	2,698
Amounts owed to group undertakings	**12,309**	9,400
Corporation tax payable	**—**	3,191
Taxation and social security	**783**	979
Finance Leases	**10**	10
Accruals and deferred income	**8,266**	15,253
	24,767	31,531

The amounts owed to group undertakings of £12,309,390 (2020: £9,400,477) are unsecured, bear no interest and are repayable on demand.

15. Creditors: amounts falling due after more than one year

	2021 £'000	2020 £'000
Finance leases	**13**	23
Amounts owed to group undertakings	**12,520**	12,520
	12,533	12,543

Included in Amounts owed to group undertakings are loan notes of £12,519,938 (2020: £12,519,938). The loan notes are unsecured, bear interest at SONIA + 2.08425% and are repayable on 5 December 2024.

16. Finance leases

The future minimum finance lease payments are as follows:

	2021 £'000	2020 £'000
Not later than one year	**11**	11
Later than one year and not later than five years	**13**	23
Total gross payments	**24**	34
Less: finance charges	**(1)**	(1)
Carrying amount of liability	**23**	33

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

17. Post-employment benefits

The company operates a defined contribution scheme. The pension cost charge for the year represents contributions payable by the company to the fund and amounted to £1,241,000 (2020: £1,097,079). The liability at the year-end for the contributions payable to the defined contribution scheme is £217,515 (2020: £nil). At year end there is no prepayment in relation to the scheme (2020: £nil).

18. Deferred tax asset

	2021	2020
	£'000	£'000
Accelerated capital allowances	**2,265**	2,225
Other timing differences	**295**	160
Deferred tax	**2,560**	2,385

Provision for deferred taxation	**Deferred tax asset £'000**
At 1 January 2021	2,385
Adjustment in respect of prior years	8
Charge to profit and loss account	167
At 31 December 2021	2,560

There are no unused tax losses or unused tax credits.

The deferred tax liability expected to reverse in 2022 is £nil (2020: £nil). The deferred tax asset expected to reverse in 2022 is £294,773. The remaining balance of £2,265,767 is expected to reverse in future years and relates to the reversal of timing differences of tangible assets.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

19. Financial Instruments

The company has the following financial instruments:

	Note	2021 £'000	2020 £'000
Financial assets at fair value through profit or loss		—	—
Financial assets that are debt instruments measured at amortised cost			
– Trade debtors	13	**50,264**	44,931
– Amounts owed by group undertakings	13	**7,057**	3,647
		57,321	48,578
Financial liabilities measured at fair value through profit or loss			
Financial liabilities measured at amortised cost			
– Trade creditors	14	**3,399**	2,698
– Amounts owed to group undertakings due within one year	14	**12,309**	9,400
– Finance Leases due within one year	14	**10**	10
– Finance Leases due after one year	15	**13**	23
– Amounts owed to group undertakings due after one year	15	**12,520**	12,520
		28,251	24,651

Derivative financial instruments

The company has no interest rate derivative financial instruments (2020: none).

20. Called up share capital

	2021 £'000	2020 £'000
Allotted and fully paid		
70,000 (2020: 70,000) ordinary shares of £1	**70,000**	70,000

Dividends	2021 £'000	2020 £'000
Total dividends paid: £0.71 (2020: £0.67) per £1 ordinary share	**50,000**	46,700

FISHER CLINICAL SERVICES UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

21. Contingent assets and liabilities

The company is a participant in a group banking arrangement under which all surplus cash balances are held as collateral for bank facilities advanced to group members. No liability is expected to arise under this arrangement.

At 31 December 2021, the company had bid and performance bonds and advance payment guarantees outstanding totalling £900,000 (2020: £900,000) in favour of HM Revenue and Customs.

22. Capital and other commitments

	2021	**2020**
	£'000	£'000
Contracts authorised for future capital expenditure not provided in the financial statements	—	—

The company had the following minimum lease payments under non-cancellable operating leases for each of the following periods:

	2021	2020
	£'000	£'000
Plant and machinery and vehicles		
Within one year	—	13
Within two to five years	**282**	309
	282	322

The company has no other off-balance sheet arrangements.

23. Related party transactions

See note 5 for disclosure of the directors' remuneration and key management compensation.

The company is exempt from disclosing other related party transactions as they are with other companies that are wholly owned within the Group.

24. Controlling parties

The immediate parent undertaking is Fisher Scientific UK Holding Company 2 whose registered office is 3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT.

The ultimate parent undertaking and controlling party is Thermo Fisher Scientific Inc. which is the largest and smallest group to consolidate these financial statements. The company is incorporated in the United States of America and its common stock is listed on the New York Stock Exchange. Copies of the financial statements of the ultimate parent company are publicly available and can be obtained from its headquarters at 168 Third Avenue, Waltham, MA 02451, USA.

DocuSign Envelope ID: 5B2A144E-16EF-4996-BFC0-F23B02CBB43C

25. Events after the balance sheet date

Management is aware of the current conflict between Russia and Ukraine and have performed an analysis to determine whether this situation impacts the company's operations. The company has continuing trade relationships with our networked site in Russia and third-party depot sites in Ukraine who provide essential distribution services to satisfy on-going customer clinical trial contracts. Management are engaged with the internal Global Trade Compliance team and will continue to follow their guidance regarding these on-going relationships. Management have concluded that the current conflict has not materially impacted the operation activities however continues to closely monitor the situation.